Caption Management’s Ginkgo Bioworks DNA Stock Holding History

Caption Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-60,000	Closed	-$875K	–	1680
2025 Q3	$875K	Buy	+60,000	New	+$718K	0.01%	1149
2023 Q1	–	Sell	-625	Closed	-$42.3K	–	1192
2022 Q4	$42.3K	Sell	625 -6,583	-91%	-$605K	﹤0.01%	1183
2022 Q3	$899K	Buy	+7,208	New	+$859K	0.01%	899

Other funds holding DNA

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caption Management's DNA Position: Q4 2025 in Review

Caption Management sold out of Ginkgo Bioworks (DNA) in Q4 2025, closing a stake of 15,000 shares — an estimated $219K sold.

Caption Management first reported a position in DNA in Q4 2021 and held it in 4 quarters. The position peaked at $943K in Q3 2024. 180 funds tracked by Wall St. Rank hold DNA as of Q4 2025.

Caption Management reported no remaining Ginkgo Bioworks position as of Q4 2025 after selling out during the quarter.
Caption Management sold 15,000 Ginkgo Bioworks shares in Q4 2025, an estimated $219K.
Caption Management first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 4 quarters.
Caption Management's Ginkgo Bioworks position peaked at $943K in Q3 2024.
180 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.